We retrospectively analyzed the effect of maintenance endocrine therapy (MET) after high-dose chemotherapy with hematopoietic progenitor cell transplant (HDCT) on the progression-free survival (PFS) of patients with hormone-dependent metastatic breast cancer (MBC). One hundred and nine consecutive patients with estrogen receptor (ER) and/or progesterone receptor (PgR)-positive MBC, who were progression free for at least 4 months after HDCT with cyclophosphamide, carmustine and thiotepa (CBT), were analyzed. Of these, 55 were non-randomly submitted to MET. After a median follow-up of 34.4 months (17.1-91.0), univariate analysis showed that MET was significantly associated with improved median PFS (31.1 vs 19.2 months, P = 0.022). Complete response to HDCT, pattern of metastatic spread, extent of the disease, single vs multiple metastatic sites, prior endocrine therapy for metastatic disease and prior exposure to any hormonal therapy (adjuvant and/or for the advanced disease) were also associated with PFS at univariate analysis. A multivariate Cox proportional hazard model was fitted to the data in order to correct the effect of MET for the other significant covariates. After correcting for these covariates, MET was still significant, predicting improved PFS (hazard ratio (HR) 0.580, 95% CI; 0.362-0.931). Administration of MET after optimal cytoreduction might result in increased efficacy of HDCT in hormonedependent metastatic breast cancer.
Despite initial promising results, high-dose chemotherapy with hematopoietic progenitor cell transplant (HDCT) has not been clearly established. 1, 2 Several randomized trials are still underway which may shed light on this controversial area of oncology. 3 Retrospective analyses of metastatic breast cancer patients, have found that the use of HDCT is consistently associated with higher objective response and complete response rate (CR), as a result of conversion into CR of a proportion of patients with partial or no response to standard-dose chemotherapy (SDC). [4] [5] [6] [7] [8] The achievement of a CR to either SDC or HDCT results in increased progression-free survival and a fraction of patients achieve long-term survival. 4, 9, 10 The use of endocrine therapy is well established in patients with hormone-dependent metastatic breast cancer. 11, 12 The role of maintenance endocrine therapy (MET) in controlling the regrowth of hormone-dependent clones after maximum cytoreduction with SCD followed by HDCT has not been formally evaluated.
Metastatic breast cancer patients, treated with cyclophosphamide, carmustine and thiotepa (CBT) HDCT in clinical trials at our institution, were allowed to receive MET, according to their treating physician, if they had achieved a CR, partial response (PR), or stable disease (SD) to the high-dose program. The purpose of the current retrospective analysis was to assess the impact of MET on progression-free survival after transplant in the subgroup of patients with positive estrogen and/or progesterone receptor metastatic breast cancer, after correcting for other covariates.
Patients and methods
Patients were selected from 232 consecutive women with MBC, who underwent HDCT consisting of cyclophosphamide, carmustine and thiotepa (CBT) on several different protocols at The University of Texas MD Anderson Cancer Center between August 1991 and December 1998.
Patients received induction SDC with the intent to produce a maximum cytoreduction before starting HDCT. To be eligible for HDCT, patients had to be between 18 and 65 years old and have a Zubrod performance status Ͻ1, an estimated creatinine clearance Ͼ60 ml/min, SGOT, SGPT and bilirubin levels less than twice the upper limits of normal, adequate cardiac function (left ventricular ejection fraction Ͼ50%), and adequate pulmonary function (DLCO Ͼ50% of predicted).
The extent of metastatic disease was assessed using the scoring system developed by Swenerton et al. 13 In brief, 12 anatomical sites: ipsilateral breast, contralateral breast, lymph nodes, skin/chest wall, lung, pleura, liver, mediastinum/abdomen intraperitoneal, peritoneum, bone, bone marrow, and central nervous system were examined. The extent of disease at each site was defined as follows: 0, no disease; 1, strong suspicion of involvement but insufficient laboratory or clinical information to define further; 2, minimal involvement; 5, moderate involvement; 10 extensive involvement. The total burden of metastatic disease was estimated as the sum of the scores for tumor extent at all known disease sites. The maximum extent of metastatic disease before induction chemotherapy and the extent of metastatic disease just prior to initiation of the HDCT were determined.
Standard criteria for response were used. 14 Complete remission was defined as 100% disappearance of all known disease lasting for at least 1 month and normalization of all abnormal laboratory parameters. Complete remission in bone was defined as recalcification of all lytic osseous lesions and disappearance of all abnormal uptake areas previously noted on a bone scan, with complete absence of bone pain without analgesics. Partial remission was recorded as a 50% or greater reduction in the sum of the product of the two longest perpendicular diameters of all measurable lesions that persisted for at least 1 month. A PR in bone was considered an improvement or stabilization of radiographic assessment of disease with subjective improvement (a decrease in bone pain and lowering of analgesics by at least 50%) and improvement in performance status by one grade or more that lasted at least 3 weeks. Stable disease (SD) was defined as less than a 50% decrease or less than a 25% increase in the sum of the product of the two longest perpendicular diameters of all measurable lesions. Progressive disease (PD) was defined as a 25% or greater increase in the sum of the product of the two longer perpendicular diameters of one measurable lesion (even with regression of other lesions) or the appearance of new lesions. Early death (ED) was defined as death within 100 days after transplant, before any assessment of a response to the transplant could be made.
The Only patients with estrogen receptor (ER) and/or progesterone receptor (PgR) positive metastatic breast cancer were selected for this analysis.
The characteristics of patients receiving (MET) or not receiving (NoMET) post-transplant endocrine therapy were compared using the Chi-square test for categorical variables. Since age was normally distributed in the two groups, comparison was made by the Student's t-test. In order to avoid a bias potentially introduced by events, progression or death, occurring before the intended treatment could have been administered, a landmark for the survival analysis was established 4 months after the date of transplant. Overall survival (OS) was calculated from the date of transplant to the date of death from any cause. Progression-free survival (PFS) was calculated from the date of transplant to the date of disease progression or death from any cause. Kaplan-Meier estimates of progression-free survival, were then found for each level of the various potential prognostic factors in a univariate fashion and compared by the logrank test. Those factors which were found to have statistically significant differences between strata (P value Ͻ0.05) were then analyzed together in a multivariate Cox proportional hazards regression model. Results are reported as estimated hazard ratio (HR) and confidence intervals for the HR. P values were calculated by means of the Wald statistic, and considered significant at the 0.05 level. Statistical analysis was performed using the SPSS-PC software (SPSS, Chicago, IL, USA).
Results
The selection process for this retrospective analysis is outlined in Figure 1 .
After high-dose chemotherapy and hematopoietic pro- genitor cell transplantation, 103 patients were in CR (44%), 40 attained a further tumor response with respect to their status before transplant (PR, 17%), 64 patients (20 in SD, 38 in PR and six in PD before transplant) had 'no change' in their disease status (SD, 28%), 14 patients progressed (PD, 6%), and 11 patients died from transplant-related complications (ED, 5%). Of the 207 patients who had attained an objective response or disease stabilization after transplant, 124 had ER and/or PgR receptor positive primary tumor. Of these patients, 65 received post-transplant maintenance endocrine therapy (MET). Nine patients in the MET group and one patient in the NoMET group were excluded from the analysis because they received posttransplant chemotherapy for residual disease. Another five patients, one in the MET group and four in the NoMET group, relapsed within 4 months from transplant and were excluded from the analysis (see Materials and methods). Table 1 summarizes the characteristics of the two groups of patients (MET and noMET). Although differences were not statistically significant, more patients in the NoMET group had been previously exposed to endocrine therapy (adjuvant and/or for the advanced disease, 59% vs 44%), and had visceral involvement (44% vs 31%). Moreover, NoMET patients tended to have more extensive disease, measured as maximum Swenerton score before induction chemotherapy. Most of the patients (87% and 85% in the MET and NoMET group, respectively) underwent HDCT after first-line conventional chemotherapy for metastatic disease.
All the patients previously treated with adjuvant endocrine therapy received tamoxifen. Of the 30 patients who had received endocrine therapy for metastatic disease, nine (five in the MET and four in the NoMET groups) had also received a second-line hormonal compound upon progression to the first line used. Table 2 summarizes the endocrine treatments used as first-line, second-line and MET, respectively.
At a median follow-up of 34.4 months (range 17.1-91.0), the Kaplan-Meier estimates of median OS and PFS for all the patients were 54.0 and 21.3 months, respectively. There was a trend for better OS in patients receiving MET (median 76.5 vs 41.7 months), but this was not statistically significant (P = 0.11) (Figure 2a) . MET was significantly associated with prolonged PFS (median 31.1 vs 19.2 months, P = 0.022) (Figure 2b) . The results of univariate analysis of factors affecting PFS are summarized in Table  3 . Other covariates found to be significant at the univariate level were complete response at the end of the transplant program (CR), maximum extent of the disease at any time and extent of the disease at the time of HDCT as measured by the Swenerton score, single vs multiple site of metastatic involvement, dominant site of disease, prior exposure to endocrine therapy for metastatic disease and prior exposure to any endocrine therapy, whether in the adjuvant setting or for metastatic disease. A Cox proportional hazard model was fitted to these data in order to study the independent effect of post-transplant endocrine maintenance therapy on PFS, after correcting for the other significant covariates. Response to HDCT was dichotomized as CR vs PR and SD; dominant site of metastatic disease was dichotomized as bone vs others; extent of disease measured by the Bone Marrow Transplantation Swenerton score was dichotomized as Ͼ20 vs р20. The results of this analysis are summarized in Table 4 .
The following factors were found to be independently associated with improved PFS: CR to HDCT (HR 0.296, 95% CI; 0.172-0.510), and MET (HR 0.580, 95% CI; 0.362-0.931). The following factors were independently associated with worse PFS: maximum extent of metastatic disease Ͼ20 by the Swenerton score (HR 2.353, 95% CI; 1.293-4.281) and prior exposure to endocrine therapy (any) (HR 1.651, 95% CI; 1.005-2.716). Figure 3a and b shows the Kaplan-Meier estimates of PFS according to MET in patients achieving (a) or not achieving (b) a CR to HDCT. MET was associated with better PFS in patients in CR after transplant (3 years PFS, 75.5% vs 38.4%), although this difference was of borderline statistical significance (log-rank test, P = 0.06) (Figure 3a) . Similarly MET conferred a non-significant PFS benefit to patients failing to achieve a CR to HDCT (3-year PFS 21% vs 7.7%, log-rank test, P = 0.12) (Figure 2b) .
Discussion
This retrospective analysis shows that the administration of MET resulted in a longer progression-free interval achieved by HDCT in hormone receptor-positive metastatic breast cancer patients. MET retained independent prognostic patients with hormone-dependent metastatic breast cancer. Another small study in metastatic breast cancer patients receiving conventional epirubicin therapy suggested a possible survival benefit from MET. 15 The only randomized trial assessing the role of MET in MBC patients has shown a modest improvement in PFS of MBC patients responding to six cycles of epirubicin and ifosfamide; 16 the administration of medroxyprogesterone acetate to 46 patients resulted in a PFS gain of 1.2 months Bone Marrow Transplantation compared to 44 patients in the control group. The small sample size, the inclusion of receptor-negative patients, and the use of an older generation endocrine compound limit the interpretation of this trial.
In our study, 13 (23%) MET patients and 17 (31%) NoMET patients received endocrine therapy for metastatic disease and progressed before they were considered for HDCT. Their tumors could therefore be considered refractory to the hormonal compound administered. On univariate analysis, this factor had a detrimental effect on PFS (13.3 vs 26.6 months, P = 0.018), which disappeared in the multivariate model. Any prior exposure to endocrine therapy (adjuvant or for metastatic disease) retained an independent value in predicting worse PFS at the multivariate analysis (HR for progressive disease 1.651, P = 0.048), suggesting that selection of hormone refractory, aggressive clones might have taken place in extensively pretreated patients. The availability of newer hormonal compounds, with increased efficacy and improved tolerance, may provide more therapeutic options for MET in patients who have previously progressed during hormonal treatment. [17] [18] [19] [20] [21] [22] We found a trend towards longer OS in patients receiving MET (Figure 1a) , which may become significant with longer follow-up. We speculate that, since treatment upon progression after HDCT is expected to have only a marginal effect on the natural history of metastatic breast cancer, 23 delaying disease progression by maintenance therapy might eventually result in longer survival. Moreover, prolonged PFS would have a positive impact on quality of life in metastatic breast cancer patients, especially after the toxic burden of HDCT.
The retrospective design and the small sample size do not allow us to draw any firm conclusion about the role of MET in metastatic breast cancer patients responding to conventional or high-dose chemotherapy, a randomized trial being the most appropriate method to address this issue. In fact, although no significant imbalance in the distribution of baseline prognostic factors was found between the two groups, more patients in the NoMET group had been previously exposed to endocrine therapy (adjuvant and/or for the advanced disease, 59% vs 44%), and had visceral involvement (44% vs 31%). Moreover, NoMET patients tended to have more extensive disease, measured as maximum Swenerton score before induction chemotherapy. One obvious consideration is that the choice of giving or not giving MET after HDCT might have been biased in favor of patients with better prognosis (non-visceral disease, limited disease extent, no prior exposure to endocrine therapy).
In summary, MET was independently associated with better PFS in this selected group of patients. CR is a requisite for long-term survival, and MET confers an additional advantage to patients in CR (Figure 3a and b) . Very extensive metastatic disease before HDCT (Swenerton score Ͼ20) predicts worse PFS. Patients pretreated with endocrine compounds had increased risk for relapse (more aggressive tumor behavior?).
The detrimental effect of prior exposure to endocrine compounds, if confirmed in larger analyses or prospectively, is likely to have an impact on the optimal timing of administration of endocrine compounds in this group of patients. In an ideal randomized trial, HDCT should be given upfront in endocrine-dependent metastatic breast cancer patients and, once maximum cytoreduction is achieved, endocrine therapy should follow.
High-dose chemotherapy remains a promising approach to improve cytoreduction in patients with breast cancer. Ongoing randomized trials will hopefully clarify the efficacy of the general approach and identify subsets of patients in whom this approach is indicated. Our observation suggests that controlling tumor regrowth after maximally reduced tumor burden might result in increased efficacy of HDCT. The same rationale could be extended to other promising developmental strategies to eradicate drug resistant minimal residual disease, such as immunotherapy, or therapy with antiangiogenic factors.
